|
|
|
|
|
|
|
|
|
|
|
13.10.26 - 22:31
|
Teradyne to Announce Third Quarter 2026 Results (Business Wire)
|
|
|
NORTH READING, Mass.--(BUSINESS WIRE)--Teradyne, Inc. (NASDAQ: TER) will release financial results for the third quarter 2026 on Tuesday, October 27, 2026 at 4:30 p.m. Eastern Time (ET) or later.A conference call to discuss the third quarter results, along with management's business outlook, will follow at 8:30 a.m. ET, Wednesday, October 28, 2026.Interested investors should access the webcast at investors.teradyne.com/events-presentations at least five minutes before the call begins. Presentation materials will be available starting at 7:30 a.m. ET.A replay will be available on the Teradyne website at investors.teradyne.com.About TeradyneTeradyne (NASDAQ:TER) designs, develops, and manufactures automated test equipment and advanced robotics systems. Its test solutions for semiconductors and electronics products enable Teradyne's customers to consistently deliver on their quality standards. Its advanced robotics business includes collaborative robots and mobile robots that support manufacturing and ware...
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
|
06.10.26 - 20:30
|
Multiply Labs Raises $75 Million Series B to Close the Gap Between Drug Discovery and Drug Manufacturing (Business Wire)
|
|
|
Series B funding will strengthen Multiply Labs' momentum scaling the robotic manufacturing platform turning AI-discovered drugs into treatments patients can receive.SAN FRANCISCO--(BUSINESS WIRE)--Multiply Labs, the physical AI company automating some of the most complex manufacturing processes in medicine, today announced a $75 million Series B, bringing its total capital raised to over $100 million since its founding in 2016. The round was led by Dr. Patrick Soon-Shiong with NantWorks, with new investors AstraZeneca, Lingotto, Teradyne, and Strange Ventures, and returning investors Casdin Capital, Lux Capital, Fifty Years, Ora Global, and Founders Fund, among others.
Tens of billions of dollars are pouring into AI-drug discovery, but drug manufacturing timelines have remained largely the same. As AI accelerates drug discovery, manufacturing is becoming a critical constraint, determining how quickly—or slowly—new therapies reach the patients waiting for them. Some of the most complex processes in bi...
|
|
|
|
|
|
|
|
|
|
|
|
Börsentreff auf Facebook |
Börsentreff auf X |
Börsentreff auf Instagram
